Article
Rheumatology
Amy Cunningham-Bussel, Jiaqi Wang, Lauren C. Prisco, Lily W. Martin, Kathleen M. M. Vanni, Alessandra Zaccardelli, Mazen Nasrallah, Lydia Gedmintas, Lindsey A. MacFarlane, Nancy A. Shadick, Mark M. Awad, Osama Rahma, Nicole R. LeBoeuf, Ellen M. Gravallese, Jeffrey A. Sparks
Summary: This study aimed to identify predictors of rheumatic immune-related adverse events (irAEs) following immune checkpoint inhibitor (ICI) treatment for cancer. Through a case-control study, it was found that baseline presence of melanoma, genitourinary (GU) cancer, autoimmune disease, receiving combination ICI treatment, and glucocorticoid use were predictors of rheumatic irAEs.
ARTHRITIS & RHEUMATOLOGY
(2022)
Review
Endocrinology & Metabolism
T. Anders Olsen, Tony Zibo Zhuang, Sarah Caulfield, Dylan J. Martini, Jacqueline T. Brown, Bradley C. Carthon, Omer Kucuk, Wayne Harris, Mehmet Asim Bilen, Bassel Nazha
Summary: Immune-oncologic therapy has revolutionized cancer treatment, but immune-related adverse events (irAEs) can occur as side effects. irAEs are major consequences of checkpoint inhibitors and significantly impact a patient's cancer treatment and quality of life. Therefore, it is important to manage irAEs using a similar approach to autoimmune diseases.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Oncology
Kristen Mathias, Sherin Rouhani, Daniel Olson, Anne R. Bass, Thomas F. Gajewski, Pankti Reid
Summary: This article examines the clinical utility of rheumatic autoantibodies (rhAbs) in diagnosing immune-related adverse events (irAEs). The study finds a significant association between rhAbs and rheumatic irAEs, and shows that irAEs are linked to better overall survival.
Review
Oncology
Steven Nicolaides, Alex Boussioutas
Summary: Immunotherapy is an effective cancer treatment that activates the immune system to target and destroy cancer cells. However, the use of immune checkpoint inhibitors is often limited by immune-related adverse events. This review focuses on the management and emerging therapies for immune-related adverse events in the gastrointestinal system.
Article
Immunology
Li Zeng, Gang Ma, Kai Chen, Qiao Zhou
Summary: This study examined the trend of ICIs-associated rheumatic irAEs using bibliometric methods, finding that the United States is the leading contributor and observing shifts in research focus through keyword analysis and citation bursts.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Nilasha Ghosh, Michael Postow, Chengsong Zhu, Deanna Jannat-Khah, Quan-Zhen Li, Greg Vitone, Karmela K. Chan, Anne R. Bass
Summary: Immune checkpoint inhibitors have shown success in treating advanced cancers but can also lead to immune-related adverse events (irAE). This study investigated the association between baseline autoantibodies and irAE development in patients receiving ICI therapy for melanoma. Results showed that lower autoantibody concentrations at baseline and a greater change in antibody concentration over time were associated with organ-specific irAE. Further research is needed to understand the role of autoantibodies in the pathogenesis of irAE.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Biochemistry & Molecular Biology
Quang Minh Dang, Ryu Watanabe, Mayu Shiomi, Kazuo Fukumoto, Tomomi W. Nobashi, Tadashi Okano, Shinsuke Yamada, Motomu Hashimoto
Summary: With the increase in elderly patients, malignancies are becoming more common in rheumatoid arthritis (RA) patients and often pose challenges to RA treatment. Immune checkpoint inhibitors (ICIs) have emerged as a promising treatment option for various malignancies by blocking immunological brakes on T lymphocytes. However, ICIs are also associated with numerous immune-related adverse events (irAEs) including hypophysitis, myocarditis, pneumonitis, and colitis. Moreover, ICIs can exacerbate existing autoimmune diseases and cause rheumatic irAEs such as arthritis, myositis, and vasculitis. This review provides a comprehensive summary of the mechanisms, management, and potential therapeutic strategies for rheumatic irAEs.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Carly C. Barron, Isabella Stefanova, Yevin Cha, Karam Elsolh, Arman Zereshkian, Nessma Gaafour, Elaine McWhirter
Summary: Immune-related adverse events (irAEs) are toxicities resulting from use of immune checkpoint inhibitors (ICIs). These side effects persist in some patients despite withholding therapy and using immunosuppressive and immune-modulating agents. Little is known about chronic irAEs and they are felt to be rare.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Karolina Gente, Leonore Diekmann, Lea Daniello, Julia Will, Manuel Feisst, Victor Olsavszky, Janine Guenther, Hanns-Martin Lorenz, M. Margarida Souto-Carneiro, Jessica C. Hassel, Petros Christopoulos, Jan Leipe
Summary: The study found that male sex, flare of pre-existing rheumatologic conditions, and extensive glucocorticoid treatment were associated with unfavorable cancer outcomes, while the use of disease-modifying antirheumatic drugs had a positive impact.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Jarushka Naidoo, Catherine Murphy, Michael B. Atkins, Julie R. Brahmer, Stephane Champiat, David Feltquate, Lee M. Krug, Javid Moslehi, M. Catherine Pietanza, Joanne Riemer, Caroline Robert, Elad Sharon, Maria E. Suarez-Almazor, Karthik Suresh, Michelle Turner, Jeffrey Weber, Laura C. Cappelli
Summary: Immune checkpoint inhibitor (ICI) therapy can lead to immune-related adverse events (irAEs) that vary in their clinical presentation, making it challenging to apply clinical guidelines due to inconsistent terminology. A consensus panel composed of international experts developed clinical definitions for irAE terminology to establish a standardized vocabulary and improve the uniform application of guidelines and future clinical trials.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Julie R. Brahmer, Hamzah Abu-Sbeih, Paolo Antonio Ascierto, Jill Brufsky, Laura C. Cappelli, Frank B. Cortazar, David E. Gerber, Lamya Hamad, Eric Hansen, Douglas B. Johnson, Mario E. Lacouture, Gregory A. Masters, Jarushka Naidoo, Michele Nanni, Miguel-Angel Perales, Igor Puzanov, Bianca D. Santomasso, Satish P. Shanbhag, Rajeev Sharma, Dimitra Skondra, Jeffrey A. Sosman, Michelle Turner, Marc S. Ernstoff
Summary: ICIs are standard treatments for cancer, but come with risks of immune-related adverse events. The SITC convened an expert panel to develop guidelines for managing irAEs, aiming to improve patient outcomes through evidence-based recommendations.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Jordyn Silverstein, Francis Wright, Michelle Wang, Arabella Young, Daniel Kim, Kimberly De Dios, Sam Brondfield, Zoe Quandt
Summary: By analyzing patients hospitalized for immune-related adverse events (irAEs), this study finds that survival outcomes vary across irAEs, immune checkpoint inhibitors (CPIs), and cancer types.
Review
Oncology
Guilherme Sacchi de Camargo Correia, Tanmayi Pai, Shenduo Li, Dana Connor, Yujie Zhao, Yanyan Lou, Rami Manochakian
Summary: The manuscript reviews the clinical trials of immune checkpoint inhibitors (ICI) for the treatment of lung cancer between 2015 and 2023 and investigates the frequency of immune-related adverse events (irAEs) in this patient population. The most common and relevant adverse events associated with ICI, including hypothyroidism, pneumonitis, diarrhea/colitis, skin rash, and hepatitis, are discussed. The association between irAEs and disease response is also explored.
CURRENT ONCOLOGY REPORTS
(2023)
Article
Oncology
Florentia Dimitriou, Sabrina Hogan, Alexander M. Menzies, Reinhard Dummer, Georgina Long
Summary: The study showed that tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, demonstrated effectiveness in treating or preventing autoimmune irAE in patients receiving ICIs. Tocilizumab improved clinical outcomes and C-reactive protein levels, while being well tolerated.
EUROPEAN JOURNAL OF CANCER
(2021)
Review
Biology
Anca Bobirca, Florin Bobirca, Ioan Ancuta, Alesandra Florescu, Vlad Padureanu, Dan Nicolae Florescu, Rodica Padureanu, Anca Florescu, Anca Emanuela Musetescu
Summary: Cancer therapy has evolved over the years, with immunotherapy being widely used for untreatable malignant tumors. Although immune checkpoint inhibitors have a significant impact on cancer treatment, they are associated with various adverse effects, mostly inflammation. These adverse events can affect various tissues in the human body, requiring a multidisciplinary approach for management.